Imagion Biosystems Limited (ASX: IBX) has lodged “Appendix 3B: New issue announcement, application for quotation of additional securities and agreement” with the Australian Securities Exchange.View “Appendix 3B: New issue announcement”
Quarterly Activity Report – Quarter ending 31 December 2023
January 31, 2024
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal